Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

The stock's fall snapped a five-day winning streak.

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich’s ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...